Reverse DCF
What growth does the market imply for NATCOPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
conservative
2.9% implied annual FCF growth
The market is pricing in below-GDP growth — very conservative assumption. If the company delivers anywhere near its historical rate, there is significant upside.
Current Price
₹1,087
Historical Growth
18.0%
FCF Yield
6.09%
Price / FCF
16.4x
Plain English
To justify today's price of $1087.00, NATCOPHARM.NS needs to grow its free cash flow at 2.9% per year for the next 10 years. That is 15.1% slower than its historical growth rate of 18.0%. This looks achievable — the market is not pricing in heroic assumptions. There may be genuine upside if the company executes.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Half implied | 1.4% | ₹971 | -10.6% |
| Implied | 2.9% | ₹1,089 | +0.2% |
| GDP rate | 10.0% | ₹1,928 | +77.4% |
| Historical | 18.0% | ₹3,653 | +236.1% |
At Historical Growth Rate
It would take 3 years for NATCOPHARM to organically grow into today's price assuming its historical FCF growth of 18.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.